Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1975 3
1976 6
1977 2
1978 1
1979 4
1980 3
1981 2
1982 5
1983 2
1984 2
1985 1
1986 3
1987 8
1988 10
1989 14
1990 12
1991 11
1992 6
1993 18
1994 14
1995 25
1996 27
1997 25
1998 24
1999 32
2000 34
2001 21
2002 20
2003 23
2004 19
2005 32
2006 31
2007 23
2008 25
2009 24
2010 16
2011 19
2012 28
2013 27
2014 28
2015 19
2016 17
2017 15
2018 12
2019 15
2020 14
2021 9
2022 19
2023 19
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

720 results

Results by year

Filters applied: . Clear all
Page 1
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
Ishihara M, Kitano S, Kageyama S, Miyahara Y, Yamamoto N, Kato H, Mishima H, Hattori H, Funakoshi T, Kojima T, Sasada T, Sato E, Okamoto S, Tomura D, Nukaya I, Chono H, Mineno J, Kairi MF, Diem Hoang Nguyen P, Simoni Y, Nardin A, Newell E, Fehlings M, Ikeda H, Watanabe T, Shiku H. Ishihara M, et al. Among authors: shiku h. J Immunother Cancer. 2022 Jun;10(6):e003811. doi: 10.1136/jitc-2021-003811. J Immunother Cancer. 2022. PMID: 35768164 Free PMC article. Clinical Trial.
Microarray-Based Electrochemical Biosensing.
Ino K, Utagawa Y, Shiku H. Ino K, et al. Among authors: shiku h. Adv Biochem Eng Biotechnol. 2023 Jun 13. doi: 10.1007/10_2023_229. Online ahead of print. Adv Biochem Eng Biotechnol. 2023. PMID: 37306698
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Ishihara M, Nishida Y, Kitano S, Kawai A, Muraoka D, Momose F, Harada N, Miyahara Y, Seo N, Hattori H, Takada K, Emori M, Kakunaga S, Endo M, Matsumoto Y, Sasada T, Sato E, Yamada T, Matsumine A, Nagata Y, Watanabe T, Kageyama S, Shiku H. Ishihara M, et al. Among authors: shiku h. Int J Cancer. 2023 Jun 15;152(12):2554-2566. doi: 10.1002/ijc.34453. Epub 2023 Feb 17. Int J Cancer. 2023. PMID: 36727538 Clinical Trial.
Biofabrication Using Electrochemical Devices and Systems.
Ino K, Ozawa F, Dang N, Hiramoto K, Hino S, Akasaka R, Nashimoto Y, Shiku H. Ino K, et al. Among authors: shiku h. Adv Biosyst. 2020 Apr;4(4):e1900234. doi: 10.1002/adbi.201900234. Epub 2020 Jan 29. Adv Biosyst. 2020. PMID: 32293161 Review.
Exosome-mediated regulation of tumor immunology.
Seo N, Akiyoshi K, Shiku H. Seo N, et al. Among authors: shiku h. Cancer Sci. 2018 Oct;109(10):2998-3004. doi: 10.1111/cas.13735. Epub 2018 Aug 1. Cancer Sci. 2018. PMID: 29999574 Free PMC article. Review.
Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4.
Alsalloum A, Shevchenko J, Fisher M, Philippova J, Perik-Zavodskii R, Perik-Zavodskaia O, Alrhmoun S, Lopatnikova J, Vasily K, Volynets M, Zavjalov E, Solovjeva O, Akahori Y, Shiku H, Silkov A, Sennikov S. Alsalloum A, et al. Among authors: shiku h. Int J Mol Sci. 2023 Oct 13;24(20):15134. doi: 10.3390/ijms242015134. Int J Mol Sci. 2023. PMID: 37894816 Free PMC article.
Classification of current anticancer immunotherapies.
Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. Galluzzi L, et al. Among authors: shiku h. Oncotarget. 2014 Dec 30;5(24):12472-508. doi: 10.18632/oncotarget.2998. Oncotarget. 2014. PMID: 25537519 Free PMC article. Review.
720 results